Title:
USE OF BACTEROIDES FRAGILIS COMBINED WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF SKIN TUMORS
Document Type and Number:
WIPO Patent Application WO/2023/134195
Kind Code:
A1
Abstract:
Disclosed is the use of Bacteroides fragilis combined with an immune checkpoint inhibitor in the treatment of skin tumors, in particular to the combination of Bacteroides fragilis ZY-312 with the deposit number of CGMCC No. 10685 and a PD-1 inhibitor, which can significantly improve the comprehensive efficacy of treating skin tumors. By means of reducing the levels of proinflammatory factors IL-1, IL-6, IL-8 and VEGF, increasing the migration of CD8+ effector T cells and reducing the recruitment of Treg cells, Bacteroides fragilis can reduce the weight of in-situ tumors and increase the cancer inhibition rate so as to effectively prevent and treat the occurrence, development, recurrence and metastasis of melanoma, reduce the harm of radiotherapy and chemotherapy to the body, and improve the quality of life of patients.
Inventors:
WANG YE (CN)
ZHENG LIJUN (CN)
HUANG SHUOYA (CN)
WU JIAQI (CN)
ZHENG LIJUN (CN)
HUANG SHUOYA (CN)
WU JIAQI (CN)
Application Number:
PCT/CN2022/119441
Publication Date:
July 20, 2023
Filing Date:
September 16, 2022
Export Citation:
Assignee:
GUANGZHOU ZHIYI BIOTECHNOLOGY CO LTD (CN)
International Classes:
A61K45/06; A61K35/741; A61K39/395; A61P35/00; C07K14/195
Domestic Patent References:
| WO2017071347A1 | 2017-05-04 |
Foreign References:
| CN109528775A | 2019-03-29 | |||
| CN109793761A | 2019-05-24 | |||
| EP3795676A1 | 2021-03-24 | |||
| US20210069260A1 | 2021-03-11 | |||
| CN103142656A | 2013-06-12 | |||
| CN114344339A | 2022-04-15 |
Other References:
SALEK FARROKHI AMIR, DARABI NARGES, YOUSEFI BAHMAN, ASKANDAR RAFEE HABIB, SHARIATI MANSOREH, ESLAMI MAJID: "Is it true that gut microbiota is considered as panacea in cancer therapy?", JOURNAL OF CELLULAR PHYSIOLOGY, WILEY SUBSCRIPTION SERVICES, INC., US, vol. 234, no. 9, 1 September 2019 (2019-09-01), US , pages 14941 - 14950, XP093078743, ISSN: 0021-9541, DOI: 10.1002/jcp.28333
M. VETIZOU, J. M. PITT, R. DAILLERE, P. LEPAGE, N. WALDSCHMITT, C. FLAMENT, S. RUSAKIEWICZ, B. ROUTY, M. P. ROBERTI, C. P. M. DUON: "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 350, no. 6264, 27 November 2015 (2015-11-27), US , pages 1079 - 1084, XP055691620, ISSN: 0036-8075, DOI: 10.1126/science.aad1329
HEFFERNAN ISABELLA M., MCGEARY JOHN E., CHUNG CHUN-SHIANG, AYALA ALFRED, HEFFERNAN DAITHI S.: "Unmasking Unique Immune Altering Aspects of the Microbiome as a Tool to Correct Sepsis-Induced Immune Dysfunction", SURGICAL INFECTIONS, MARY ANN LIEBERT, LARCHMONT, NY, US, vol. 22, no. 4, 1 May 2021 (2021-05-01), US , pages 400 - 408, XP093078740, ISSN: 1096-2964, DOI: 10.1089/sur.2020.233
M. VETIZOU, J. M. PITT, R. DAILLERE, P. LEPAGE, N. WALDSCHMITT, C. FLAMENT, S. RUSAKIEWICZ, B. ROUTY, M. P. ROBERTI, C. P. M. DUON: "Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 350, no. 6264, 27 November 2015 (2015-11-27), US , pages 1079 - 1084, XP055691620, ISSN: 0036-8075, DOI: 10.1126/science.aad1329
HEFFERNAN ISABELLA M., MCGEARY JOHN E., CHUNG CHUN-SHIANG, AYALA ALFRED, HEFFERNAN DAITHI S.: "Unmasking Unique Immune Altering Aspects of the Microbiome as a Tool to Correct Sepsis-Induced Immune Dysfunction", SURGICAL INFECTIONS, MARY ANN LIEBERT, LARCHMONT, NY, US, vol. 22, no. 4, 1 May 2021 (2021-05-01), US , pages 400 - 408, XP093078740, ISSN: 1096-2964, DOI: 10.1089/sur.2020.233
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF: